Pluri (PLUR) Degree of Financial Leverage : -0.72 (As of Mar. 2026)


PLUR Pluri Inc PLUR
25 GF Score
Price $2.06
GF Value $6.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pluri Degree of Financial Leverage?

Pluri PLUR -1.67% 25 Degree of Financial Leverage is -0.72 as of Mar. 2026. GuruFocus rates PLUR with a GF Score™ of 25/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,349 Biotechnology companies, Pluri ranks better than 86.95% on this metric.

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Pluri's Degree of Financial Leverage for the quarter that ended in Mar. 2026 was -0.72. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Pluri's Degree of Financial Leverage or its related term are showing as below:

PLUR's Degree of Financial Leverage is ranked better than
86.95% of 1349 companies
in the Biotechnology industry
Industry Median: 0.95 vs PLUR: -0.72

Pluri  (NAS:PLUR) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Pluri Degree of Financial Leverage Related Terms


Pluri Degree of Financial Leverage Historical Data

* Premium members only.

The historical data trend for Pluri's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pluri Degree of Financial Leverage Chart

Pluri Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 1.45 1.31 1.30 -1.21

Pluri Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 -1.21 -4.90 -0.31 -0.72

PLUR vs VTGN, PTN, CLRB: Degree of Financial Leverage Comparison

For the Biotechnology subindustry, Pluri's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pluri Degree of Financial Leverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Pluri's Degree of Financial Leverage falls into.


PLUR
25GF Score
Pluri Inc PLUR
Degree of Financial Leverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pluri Degree of Financial Leverage Calculation

Pluri's Degree of Financial Leverage for the quarter that ended in Mar. 2026 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.91 (Mar. 2026) / -3.62 (Mar. 2025) - 1 )/( -26.044 (Mar. 2026) / -20.485 (Mar. 2025) - 1 )
=-0.1961/0.2714
=-0.72***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

What does a Degree of Financial Leverage of -0.72 mean?
Pluri (PLUR) has a Degree of Financial Leverage of -0.72 as of Mar. 2026. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Pluri and its competitors. According to the industry distribution chart, Pluri ranks #176 out of 1349 companies in the Biotechnology industry, placing it in the top 13%.
Is Pluri's Degree of Financial Leverage too high?
Pluri's current Degree of Financial Leverage is -0.72. Based on the distribution chart, Pluri ranks #176 out of 1349 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's Degree of Financial Leverage compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #176 out of 1349 companies for Degree of Financial Leverage. This places Pluri in the top 13% of its industry — outperforming the majority of peers. The industry median Degree of Financial Leverage is 0.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Financial Leverage for a Biotechnology company?
The median Degree of Financial Leverage among Biotechnology companies is 0.95, based on 1,349 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Financial Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Financial Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Financial Leverage mean?
A high Degree of Financial Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in EBIT. View historical data for Pluri and its competitors. For the Biotechnology industry, the median Degree of Financial Leverage is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pluri's current Degree of Financial Leverage is -0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.06 — trading 68.1% below its estimated fair value. The current Degree of Financial Leverage is -0.72. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Financial Leverage calculated?
Degree of Financial Leverage is calculated from a company's financial statements. For Pluri (PLUR), the current Degree of Financial Leverage is -0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (PLUR) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of $2.06 is trading 68.1% below its estimated GF Value™ of $6.46. GuruFocus considers Pluri to be Possible Value Trap.

Key valuation signals for PLUR:

  • Degree of Financial Leverage: -0.72
  • GF Value™: $6.46 vs. price of $2.06 (68.1% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pluri Business Description

Other Exchanges PLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for PLUR

Degree of Financial Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.06
Price
$6.46
GF Value